Support

Lorem ipsum dolor sit amet:

24h / 365days

We offer support for our customers

Mon - Fri 8:00am - 5:00pm (GMT +1)

Get in touch

Cybersteel Inc.
376-293 City Road, Suite 600
San Francisco, CA 94102

Have any questions?
+44 1234 567 890

Drop us a line
info@yourdomain.com

About us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.

EN
Have any Questions? +01 123 444 555

ARCHIVE

Emotional Journey of Patients with Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic disease with a rising prevalence. Most adult EoE patients experience difficulties eating solid food and therefore they often avoid having meals with friends and family...

Tolerance to sterilised cow's milk in patients with eosinophilic oesophagitis triggered by milk

Cow's milk protein is the main food trigger for eosinophilic oesophagitis (EoE) in children and adults and should be continuously avoided once identified as such...

Fluticasone Propionate Orally Disintegrating Tablet to Treat EoE: Published results from the Phase 2 FLUTE Trial

APT-1011 is an oral disintegrating tablet (ODT) formulation of fluticasone propionate developed by Ellodi/Adare Pharmaceuticals and designed to disintegrate after put on the tongue without water...

Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis

The Swedish Watson Dysphagia Scale (S-WDS) has been used to assess dysphagia in patients with eosinophilic esophagitis (EoE) but has not been validated for this patient group...

Non-invasive biomarkers of eosinophilic esophagitis

Eosinophilic gastrointestinal disorders (EGIDs) are emerging inflammatory diseases which may involve any part of the gastrointestinal (GI) tract and lead to the eosinophilic mucosal infiltration in the absence of secondary causes of intestinal eosinophilia...

Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort

De Rooij and coworkers have shown that the incidence of EoE is still ever increasing...

Food-induced immediate response of the esophagus—A newly identified syndrome in patients with eosinophilic esophagitis

This article from a collaborative group of European and American physicians describes a new syndrome, often encountered in overlap with EoE...

Efficacy of proton pump inhibitor therapy for EoE: Results from the CONNECT Registry

PPIs currently constitutes the most commonly used first-line therapy in EoE, mainly due to its safety profile and low cost...

Psychiatric comorbidity are common in EoE

The prevalence of psychiatric disease in patients with eosinophilic esophagitis (EoE) is not fully characterized...

Practical and clinically useful algorithms for diagnosing and treating EoE

Due to its chronicity, EoE requires both short-term and long-term treatment...

EoE patients more often have food impaction in summer and fall

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition with eosinophilic infiltration of the esophageal mucosa. The most prominent symptom is dysphagia, which may result in esophageal bolus impaction in need of surgical extraction...

Conservative treatment of esophageal perforation in patients with eosinophilic esophagitis

There is evidence of an increased fragility in the inflamed esophagus of patients with eosinophilic esophagitis (EoE). We performed a systematic review on presentation, management and outcomes of and surgical interventions for esophageal perforation in these patients.

Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies

The treatment options for eosinophilic esophagitis (EoE) patients include drugs (proton pump inhibitors [PPIs], swallowed topical corticosteroids [STCs]), elimination diets, and dilation. Given the lack of data, we aimed to assess adult EoE patients' satisfaction with different EoE-specific treatment modalities...

Efficacy of therapy for eosinophilic esophagitis in real-world practice

Topical steroids, proton pump inhibitors (PPIs), and dietary interventions are recommended first- and second-line therapies for eosinophilic esophagitis (EoE). We investigated differences in their effectiveness in a real-world, clinical practice cohort of patients with EoE...

Treatment of eosinophilic esophagitis with diets: an update

Eosinophilic esophagitis (EoE) is a chronic inflammatory esophageal disease triggered and maintained predominantly by food antigens. An elimination diet that avoids the consumption of food triggers currently remains the only therapy targeting the cause of EoE...

Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review

Over the last decade, clinical experiences and research studies raised concerns regarding use of proton pump inhibitors (PPIs) as part of the diagnostic strategy for eosinophilic esophagitis (EoE). We aimed to clarify the use of PPIs in the evaluation and treatment of children and adults with suspected EoE to develop updated international consensus criteria for EoE diagnosis.

Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial

Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE).

Illuminating Elimination Diets: Controversies Regarding Dietary Treatment of Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is an immune-mediated disease triggered by food antigens for which dietary elimination treatment can induce and sustain histologic remission.

The frequency of Eosinophilic Esophagitis continues to increase, according to two population-based studies conducted in Spain and the United States

Two recent papers just published in 2018 have documented a dramatic rise in the prevalence of EoE to fect currently more than 1 in 1,000 people.

Helicobacter pylori infection does not protect against EoE: results from a large multicenter case-control study.

Helicobacter pylori (H. pylori) infects approximately 50% of the global population, with a wide variation between regions and countries.

Copyright 2024 Seaside Media. All Rights Reserved.
It will load necessary cookies, Google Fonts, Google Maps, OpenStreetMap, Youtube and Google Analytics. More details in our privacy policy and our imprint.